SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

about

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Item

http://www.wikidata.org/entity/Q58697376

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@en

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@nl

type

Item

label

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@en

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@nl

prefLabel

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@en

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@nl

P1476

SET Overexpression is Associat ...... g Adjuvant Tamoxifen Treatment

@en

P2093

Chia-Han Lee

http://www.w3.org/2001/XMLSchema#string

Chun-Teng Huang

http://www.w3.org/2001/XMLSchema#string

Chun-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Ji-Lin Chen

http://www.w3.org/2001/XMLSchema#string

Ka-Yi Lau

http://www.w3.org/2001/XMLSchema#string

Ling-Ming Tseng

http://www.w3.org/2001/XMLSchema#string

Pei-Ju Lien

http://www.w3.org/2001/XMLSchema#string

Pei-Yi Chu

http://www.w3.org/2001/XMLSchema#string

Wan-Lun Wang

http://www.w3.org/2001/XMLSchema#string

Yu-Hsiang Huang

http://www.w3.org/2001/XMLSchema#string

P2860

CIP2A inhibits PP2A in human malignancies

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Status of adjuvant endocrine therapy for breast cancer.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare.

Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.

P304

245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JCM7090245

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30154367

http://www.w3.org/2001/XMLSchema#string

P921

overexpression

P932

6162815

http://www.w3.org/2001/XMLSchema#string